Zoetis Inc primarily operates in the animal health industry.

The main competitors of Zoetis Inc in the market are Merck & Co Inc, Elanco Animal Health Inc, and Boehringer Ingelheim GmbH.

Zoetis Inc is a leading global animal health company that specializes in the discovery, development, manufacture, and commercialization of a wide range of veterinary medicines and vaccines. Founded in 1952, Zoetis has a rich history of providing innovative solutions to improve the health and well-being of animals. With a strong commitment to research and development, the company has introduced numerous cutting-edge products and technologies that have revolutionized the field of animal health. Zoetis operates in more than 100 countries, serving veterinarians, livestock producers, and pet owners worldwide. This dedication to delivering high-quality, safe, and effective animal healthcare solutions has established Zoetis as a trusted name in the industry.

Zoetis Inc., a leading animal health company, has achieved several significant milestones in its history. Since its establishment in 2013 as a spin-off from Pfizer, Zoetis has continuously strived for innovation and growth. Some noteworthy milestones include its successful initial public offering (IPO) in 2013, becoming the largest animal health IPO in history. The company has also established itself as a global leader in animal health, expanding its presence in various markets worldwide. Additionally, Zoetis has consistently focused on research and development, introducing innovative products and solutions to address the health and well-being of animals. Through its dedication and expertise, Zoetis Inc. continues to make remarkable progress in the animal health industry.

Zoetis Inc., a leading animal health company, operates in various countries and regions worldwide. With a strong global presence, Zoetis primarily serves customers in North America, Europe, Africa, Asia, and Latin America. The company's extensive network allows it to deliver innovative animal health solutions and support to a diverse range of customers across these regions. Zoetis' commitment to expanding its reach and impact in the animal health industry is reflected in its presence and operations throughout these key locations.

Zoetis Inc represents a strong set of values and corporate philosophy. As a global animal health company, Zoetis Inc is committed to improving the health and well-being of animals by providing innovative products and services. With a focus on sustainability, they strive to make a positive impact on the world we live in. Zoetis Inc values integrity, accountability, collaboration, and customer focus. Their dedication to research and development ensures the delivery of high-quality solutions for animal health. By constantly evolving and embracing technological advancements, Zoetis Inc remains at the forefront of the industry, dedicated to improving the lives of animals, the people who care for them, and the communities they serve.

Analysts currently set an average price target of 155.47 USD for the Zoetis stock (median: 155.55 USD), implying +104.4 % versus the latest price. The consensus is based on 24 analyst ratings.

Zoetis Analyst Price Targets 2026

25 analysts currently rate the Zoetis stock: 16 recommend buying, 9 holding and 0 selling. For 2026, analysts expect Zoetis to generate revenue of 9.73 B USD and earnings per share of 6.96 USD.

Zoetis Analyst Price Targets 2026

Converted at the current exchange rate, the Zoetis share trades at 67.06 EUR (77.29 USD).

The Zoetis share (ZTS) is listed on 10 stock exchanges, including: NYSE (ZTS), XETRA (ZOE.DE), Frankfurt (ZOE.F), München (ZOE.MU), Düsseldorf (ZOE.DU), London (0M3Q.L), London (0M3Q.L), SIX (Zürich) (ZOE.SW).

Zoetis Inc is a leading company in the animal health industry that focuses on the development, manufacturing, and marketing of pharmaceuticals, vaccines, and diagnostic tests for animals. The company was founded in 1952 and is based in Parsippany, New Jersey. Zoetis operates in various segments including cattle production, swine production, poultry research and diagnostics, small animal practice, equine and livestock practice, and ectoparasiticides. The company offers several products that appeal to veterinarians and farmers. In the cattle range, Zoetis offers products such as EXCEDE, an injection that ensures sustained efficacy against pathogens in cattle, DRAXXIN, an injectable antibiotic for treating cattle with respiratory diseases and BRD, and LUTALYSE, a hormone that helps cattle breeders and livestock dealers during calving. In the swine production area, Zoetis offers products such as RESFLOR GOLD, a combination of antibiotics used for treating respiratory diseases, FOSTERA, a vaccine that provides immunity against Porcine Reproductive and Respiratory Syndrome (PRRS) and facilitates the approval of PRRS-infected swine, and DRAXXIN, a treatment for swine with respiratory disease. Zoetis is also involved in poultry research and diagnostics. Products such as FLOKILL, a medication for treating coccidiosis in chickens, Amprol, a medication for treating coccidiosis in chickens, Zeppelin, a test kit for identifying salmonella in poultry, and Bio-Chr, a feed additive that increases egg production in laying hens. In the small animal practice, Zoetis offers products such as Simparica, a medication for parasites like ticks and fleas in dogs, and Revolution and Proheart, both medications for parasites in dogs and cats. Zoetis also offers products for horses and livestock, including EQUIOXX, an anti-inflammatory for horses with arthritis and kissing spine, and CONVENIA, an antibiotic for horses, cows, and sheep. Zoetis is not only involved in the development and marketing of animal pharmaceuticals, but also in educating animal owners and farmers. They provide resources and training for animal health and care, and provide research data and information to animal owners. Zoetis' business model is to provide animal owners and farmers with innovative products and services that improve animal health and help keep animals healthy. The company specializes in developing and offering safe and effective products for animals used in food production to secure the food supply. Overall, Zoetis has a strong position in the animal pharmaceutical and diagnostic sector. The company aims to make a positive contribution to animals and animal owners through innovative products and close collaboration with animal owners.

The expected revenue of Zoetis is 9.73 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Zoetis is 3.05 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Zoetis is currently 11.10. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Zoetis stock.

The price-to-sales ratio (P/S) of Zoetis is currently 3.48. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Zoetis stock.

The Eulerpool Quality Score for Zoetis is 8/10.

The ISIN of Zoetis is US98978V1035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Zoetis is A1KBYX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Zoetis is ZTS. The ticker symbol is used to trade Zoetis shares on the stock exchange.

Over the past 12 months, Zoetis paid a dividend of 2.00 USD . This corresponds to a dividend yield of about 2.59 %. For the coming 12 months, Zoetis is expected to pay a dividend of 2.52 USD.

The current dividend yield of Zoetis is 2.59 %.

Zoetis pays a dividend, distributed in the months of , , , .

Zoetis paid dividends every year for the past 13 years.

For the upcoming 12 months, dividends amounting to 2.52 USD are expected. This corresponds to a dividend yield of 3.26 %.

Zoetis is assigned to the 'Health' sector.

To receive the latest dividend of Zoetis from amounting to 0.53 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Zoetis distributed 1.8 USD as dividends.

The dividends of Zoetis are distributed in USD.